Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duffy Null-Specific Dose Modifications in Multiple Myeloma and Triple Negative Breast Cancer
NCT07341867Phase 1Recruiting
- Start
- Jul 2026
- Primary completion
- Mar 2028
- Modality
- Stealth (PEGylated) Liposomes, Conventional Liposomes, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of daratumumab, lenalidomide, bortezomib, dexamethasone, carboplatin and 4 more in multiple myeloma (MM) and triple-negative breast cancer (TNBC) (2 arms). Primary endpoints: Avoided or reduced systemic anticancer therapy (SACT) modifications per cycle and Overall cumulative incidence of neutropenic fever. Started Jul 2026; status: recruiting.
02
Drugs
daratumumablenalidomidebortezomibdexamethasonecarboplatin
03
Conditions
multiple myeloma (MM)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07341867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07341867.